Kapil K. Saharia, MD, MPH

Bachelor of Arts (B.A): Biology and English, The Johns Hopkins University, Baltimore, MD  

Master's in Public Health (M.P.H): Public Health Leadership, University of North Carolina School of Public Health, Chapel Hill, NC

Doctor of Medicine (M.D): Duke University School of Medicine, Durham, NC

Residency: Internal Medicine/Pediatrics, Yale-New Haven Hospital, New Haven, CT

Fellowship: Infectious Diseases, University of Maryland Medical Center, Baltimore, MD

Post-Doctoral Fellowship: Immunology Laboratory, Vaccine Research Center, National Institutes of Health, Bethesda, MD

Dr. Saharia received his medical degree from Duke University School of Medicine.  He completed his residency training in Internal Medicine-Pediatrics at Yale-New Haven Hospital and served as Chief Resident for Internal Medicine-Pediatrics in his fourth year. Following residency, Dr. Saharia completed a Fellowship in Infectious Diseases at the University of Maryland Medical Center.  Dr. Saharia then joined the Immunology Laboratory at the Vaccine Research Center, NIH as a post-doctoral fellow under the mentorship of Dr. Richard Koup, where he used multiparameter flow cytometry and intracellular cytokine staining techniques to identify phenotypic and functional characteristics of Mycobacterium tuberculosis-specific CD4 T cells that could discriminate between various stages of infection.

Dr. Saharia joined the Institute of Human Virology in 2012 as Assistant Professor of Medicine. He currently provides clinical consultation services primarily on the Transplant Infectious Disease Service and serves as Chief of the Transplant Infectious Disease Service (2017). His outpatient practice focuses on the care of pre- and post-solid organ transplant recipients with infectious complications, patients with infected cardiac devices, patients with infective endocarditis, and persons infected with HIV.

Dr. Saharia's research interests include infectious outcomes in solid organ transplant recipients and the diagnosis and treatment of mycobacterial infections, including tuberculosis. He is actively involved in NIH-sponsored and industry-sponsored clinical trials. 

Infectious outcomes in transplant recipients, tuberculosis, non-tuberculous mycobacterial infections, HIV

Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules on Mycobacterium tuberculosis-specific CD4+ T-cells. PLoS One. 2016; 11 (7): e0158262. 

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother. 2014;10(12):3446-54.